Terms: = Lung cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Staging
70 results:
1. The Expression and Prognostic Significance of ICOS in NSCLC Integrated Pan-cancer and Multi-Omics Analyses.
Chen M; Yan X; Hong B; Xiao Y; Qian Y
Int J Med Sci; 2024; 21(5):795-808. PubMed ID: 38616999
[No Abstract] [Full Text] [Related]
2. Missing prognostic value of soluble PD-1, pd-l1 and PD-L2 in lung cancer patients undergoing chemotherapy - A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S355-S367. PubMed ID: 38277316
[TBL] [Abstract] [Full Text] [Related]
3. Study on Targeted Drugs for Non-Small Cell NSCLC with PD-1pd-l1 Signaling Pathway.
Cao X
Stud Health Technol Inform; 2023 Nov; 308():562-567. PubMed ID: 38007784
[TBL] [Abstract] [Full Text] [Related]
4. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer.
Travelli C; Colombo G; Aliotta M; Fagiani F; Fava N; De Sanctis R; Grolla AA; Garcia JGN; Clemente N; Portararo P; Costanza M; Condorelli F; Colombo MP; Sangaletti S; Genazzani AA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37880182
[TBL] [Abstract] [Full Text] [Related]
5. Perioperative Durvalumab for Resectable Non-Small-Cell lung cancer.
Heymach JV; Harpole D; Mitsudomi T; Taube JM; Galffy G; Hochmair M; Winder T; Zukov R; Garbaos G; Gao S; Kuroda H; Ostoros G; Tran TV; You J; Lee KY; Antonuzzo L; Papai-Szekely Z; Akamatsu H; Biswas B; Spira A; Crawford J; Le HT; Aperghis M; Doherty GJ; Mann H; Fouad TM; Reck M;
N Engl J Med; 2023 Nov; 389(18):1672-1684. PubMed ID: 37870974
[TBL] [Abstract] [Full Text] [Related]
6. RUNX1 promotes proliferation and migration in non-small cell lung cancer cell lines via the mTOR pathway.
Ma H; Jiang S; Yuan Y; Li J; Li Y; Lv Y; Du T; Guan J; Jiang X; Tian L; Zheng Q; Yang L; Li Q
FASEB J; 2023 Nov; 37(11):e23195. PubMed ID: 37801076
[TBL] [Abstract] [Full Text] [Related]
7. Mediastinal lymph node removal modulates natural killer cell exhaustion in patients with non-small cell lung cancer.
Cikman DI; Esen F; Engin A; Turna A; Agkoc M; Yilmaz A; Saglam OF; Deniz G; Aktas EC
Immunol Res; 2023 Dec; 71(6):959-971. PubMed ID: 37583002
[TBL] [Abstract] [Full Text] [Related]
8. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Felip E; Altorki N; Zhou C; Vallières E; Martínez-Martí A; Rittmeyer A; Chella A; Reck M; Goloborodko O; Huang M; Belleli R; McNally V; Srivastava MK; Bennett E; Gitlitz BJ; Wakelee HA
Ann Oncol; 2023 Oct; 34(10):907-919. PubMed ID: 37467930
[TBL] [Abstract] [Full Text] [Related]
9. Performance of endobronchial ultrasound transbronchial needle aspiration as the first nodal staging procedure for the determination of programmed death ligand-1 expression in non-small cell lung cancer patients.
Polanco D; Pinilla L; Gracia-Lavedan E; Gatius S; Zuil M; Pardina M; Gómez S; Barbé F
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12459-12468. PubMed ID: 37450028
[TBL] [Abstract] [Full Text] [Related]
10. Programmed Death Ligand -1 and Gene Mutation Characterization of lung Malignancies in Patients at a Rural Hospital in Central India.
Kanthali M; Mamgain P; Dhawan P; Bhagwat G; Patel S; Purohit MR
Asian Pac J Cancer Prev; 2023 Jun; 24(6):1855-1861. PubMed ID: 37378912
[TBL] [Abstract] [Full Text] [Related]
11. Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non-Small-Cell lung cancer in a Large Community Oncology Practice.
Waterhouse DM; Ward P; Arnal S; Neubauer M; Drosick DR; Davies D; Mendenhall MA
JCO Oncol Pract; 2023 Jun; 19(6):e951-e956. PubMed ID: 37126768
[TBL] [Abstract] [Full Text] [Related]
12. Heterogeneous expression of predictive biomarkers pd-l1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing.
Kolb T; Benckendorff J; Möller P; Barth TFE; Marienfeld RB
Neoplasia; 2023 Apr; 38():100884. PubMed ID: 36812781
[TBL] [Abstract] [Full Text] [Related]
13. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
14. Diagnostic Accuracy of Slow-Capillary Endobronchial Ultrasound Needle Aspiration in Determining pd-l1 Expression in Non-Small Cell lung cancer.
Zuccatosta L; Mei F; Sediari M; Di Marco Berardino A; Bonifazi M; Barbisan F; Goteri G; Gasparini S; Gonnelli F
Adv Respir Med; 2023 Jan; 91(1):1-8. PubMed ID: 36648877
[TBL] [Abstract] [Full Text] [Related]
15. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract] [Full Text] [Related]
16. Transcriptomics in Tumor and Normal lung Tissues Identify Patients With Early-Stage Non-Small-Cell lung cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies.
Lazar V; Girard N; Raymond E; Martini JF; Galbraith S; Raynaud J; Bresson C; Solomon B; Magidi S; Nechushtan H; Onn A; Berger R; Chen H; Al-Omari A; Ikeda S; Lassen U; Sekacheva M; Felip E; Tabernero J; Batist G; Spatz A; Pramesh CS; Girard P; Blay JY; Philip T; Berindan-Neagoe I; Porgador A; Rubin E; Kurzrock R; Schilsky RL
JCO Precis Oncol; 2022 Sep; 6():e2200072. PubMed ID: 36108261
[TBL] [Abstract] [Full Text] [Related]
17. The prognostic value of a 4-factor neoimmunologic score system in non-small cell lung cancer.
Yang F; Zeng Z; Li Y; Zhang D; Wei F; Zhao H; Zhang P; Ren X
J Leukoc Biol; 2022 Dec; 112(6):1605-1619. PubMed ID: 36073781
[TBL] [Abstract] [Full Text] [Related]
18. What does radiomics do in pd-l1 blockade therapy of NSCLC patients?
Cui R; Yang Z; Liu L
Thorac Cancer; 2022 Oct; 13(19):2669-2680. PubMed ID: 36039482
[TBL] [Abstract] [Full Text] [Related]
19. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries.
Soo R; Mery L; Bardot A; Kanesvaran R; Keong TC; Pongnikorn D; Prasongsook N; Hutajulu SH; Irawan C; Manan AA; Thiagarajan M; Sripan P; Peters S; Storm H; Bray F; Stahel R
ESMO Open; 2022 Oct; 7(5):100560. PubMed ID: 35988454
[TBL] [Abstract] [Full Text] [Related]
20. FDG PET/CT for Evaluation of Immunotherapy Response in lung cancer Patients.
Léger MA; Routy B; Juneau D
Semin Nucl Med; 2022 Nov; 52(6):707-719. PubMed ID: 35636978
[TBL] [Abstract] [Full Text] [Related]
[Next]
